Copyright
©The Author(s) 2023.
World J Clin Cases. Jan 16, 2023; 11(2): 299-307
Published online Jan 16, 2023. doi: 10.12998/wjcc.v11.i2.299
Published online Jan 16, 2023. doi: 10.12998/wjcc.v11.i2.299
Laboratory evaluation | |
Baseline blood tests | Testosterone, estradiol; CBC (including Hct or Hgb); Liver enzymes, lipid profile, creatinine; Fasting glucose (and HbA1c or oral glucose tolerance test if diabetes is suspected) |
4-6 wk after starting treatment | Testosterone, estradiol; CBC (including Hct or Hgb) |
3, 6, 9, and 12 mo after starting treatment | Testosterone, estradiol; CBC (including Hct or Hgb); Liver enzymes, lipid profile, creatinine (every 6 mo); Fasting glucose (every 6 mo) |
Semiannually or annually thereafter | Testosterone, estradiol; CBC (including Hct or Hgb); Liver enzymes, lipid profile, creatinineFasting glucose (every 6 mo) |
In 50 yr of age (only if treatment is stopped or when risk factors for osteoporosis exist) and accordingly thereafter | Bone mineral density measurement |
Individualized approach | Screening tests for breast and endometrial cancer (with no prior hysterectomy) |
Clinical assessment | |
Regular clinical examination (including body weight and blood pressure measurements), evaluation of masculinization, recording and monitoring of potential side effects |
Laboratory evaluation | |
Baseline blood tests | Testosterone, estradiol; Prolactin; CBC; Liver enzymes, lipid profile, creatinine; Fasting glucose (and HbA1c or oral glucose tolerance test if diabetes is suspected); Electrolytes; Coagulation tests (in case of high risk for thrombosis) |
1 mo after starting treatment | CBC; Liver enzymes, lipid profile, creatinine; Electrolytes (if taking spironolactone) |
3, 6, 9, and 12 mo after starting treatment | Testosterone, estradiol; CBC; Liver enzymes, lipid profile, creatinine (every 6 mo); Fasting glucose (every 6 mo); Electrolytes (if taking spironolactone) |
Semiannually or annually thereafter | Testosterone, estradiol; Prolactin (every 2 yr); CBC; Liver enzymes, lipid profile, creatinine; Fasting glucose (every 6 mo); Electrolytes (if taking spironolactone) |
In 60 yr of age (or earlier if treatment is stopped after orchiectomy or when risk factors for osteoporosis exist) and accordingly thereafter | Bone mineral density measurement |
Individualized approach | Screening tests for prostate and breast cancer |
Clinical assessment | |
Regular clinical examination (including body weight and blood pressure measurements), evaluation of feminization, recording and monitoring of potential side effects |
- Citation: Milionis C, Ilias I, Koukkou E. Liver function in transgender persons: Challenges in the COVID-19 era. World J Clin Cases 2023; 11(2): 299-307
- URL: https://www.wjgnet.com/2307-8960/full/v11/i2/299.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i2.299